Kiora Pharmaceuticals Inc. KPRX
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Kiora Pharmaceuticals Inc. (KPRX) is a healthcare company listed in the US with a market value of about $5M. In the twelve months to September 30, 2026 it had revenue of $1M and net income of -$13M, a net margin of -1276.3%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -100% a year, a 5-year average ROIC of -84%.
About Kiora Pharmaceuticals
Kiora Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $669259 in 2016 to $16M in 2024, growth of about 48.7% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 4944% over three years (dilution for shareholders).
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $0 | $16M | $0 | — | $0 | $12059 | $3M | $2M | $407518 | $669259 |
| Net income | -$13M | -$11M | $4M | -$13M | -$14M | -$14M | -$7M | -$7M | -$11M | -$13M | -$13M |
| Free cash flow | -$8M | -$10M | $9M | -$10M | -$10M | -$11M | -$7M | -$8M | -$11M | -$7M | -$8M |
| EPS (diluted) | $-2.80 | $-2.64 | $0.87 | $-24.25 | $-166.95 | $-514.08 | $-536.40 | $-802.80 | $-1645.20 | $-5022.00 | $-8154.01 |
| Net margin | -1276.3% | — | 22.4% | — | — | — | -56901.6% | -264.2% | -654.2% | -3243.5% | -1993.8% |
| ROIC | — | -69.6% | 11.1% | -159.9% | -106.0% | -94.9% | -52.7% | — | -95.9% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $7.00, 469% above the current price; targets range from $7.00 to $7.00; the consensus rating is “Buy”; expected EPS is $-1.05 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Kiora Pharmaceuticals pay a dividend?
Not currently.
Is Kiora Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Kiora Pharmaceuticals scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.